
- /
- Supported exchanges
- / US
- / PLRX.NASDAQ
Pliant Therapeutics Inc (PLRX NASDAQ) stock market data APIs
Pliant Therapeutics Inc Financial Data Overview
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pliant Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pliant Therapeutics Inc data using free add-ons & libraries
Get Pliant Therapeutics Inc Fundamental Data
Pliant Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -217 976 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.6595
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pliant Therapeutics Inc News

Biotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz
(RTTNews) - Biotech stocks lit up the after-hours session on September 9, 2025, with several small- and mid-cap names posting sharp gains following fresh clinical updates, insider buying, and investor...


Pliant Therapeutics stock price target slashed by Piper Sandler
Investing.com - Piper Sandler has lowered its price target on Pliant Therapeutics (NASDAQ:PLRX) to $4.00 from $17.00 while maintaining an Overweight rating on the stock. The stock has fallen over 86% ...

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year...

3 Promising Penny Stocks With Market Caps Under $200M
Major indexes in the United States are experiencing mixed performances, with tech stocks rallying and bank stocks sliding following recent inflation data. In this context, penny stocks remain a compel...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.